156 related articles for article (PubMed ID: 19053885)
1. The use of copper-lowering therapy with tetrathiomolybdate in medicine.
Brewer GJ
Expert Opin Investig Drugs; 2009 Jan; 18(1):89-97. PubMed ID: 19053885
[TBL] [Abstract][Full Text] [Related]
2. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
3. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
Brewer GJ
J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
[TBL] [Abstract][Full Text] [Related]
4. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
Brewer GJ
J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
[TBL] [Abstract][Full Text] [Related]
6. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
Brewer GJ
Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
Hou G; Abrams GD; Dick R; Brewer GJ
Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
[TBL] [Abstract][Full Text] [Related]
8. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
9. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
Brewer GJ
Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
11. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Brewer GJ
Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
[TBL] [Abstract][Full Text] [Related]
12. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
[TBL] [Abstract][Full Text] [Related]
13. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
Khan G; Merajver S
Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
[TBL] [Abstract][Full Text] [Related]
16. Tetrathiomolybdate, a copper chelator inhibited imiquimod-induced skin inflammation in mice.
Hsu PY; Yen HH; Yang TH; Su CC
J Dermatol Sci; 2018 Oct; 92(1):30-37. PubMed ID: 30126748
[TBL] [Abstract][Full Text] [Related]
17. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
18. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
George GN; Pickering IJ; Harris HH; Gailer J; Klein D; Lichtmannegger J; Summer KH
J Am Chem Soc; 2003 Feb; 125(7):1704-5. PubMed ID: 12580588
[TBL] [Abstract][Full Text] [Related]
19. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
Hou G; Dick R; Brewer GJ
Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
[TBL] [Abstract][Full Text] [Related]
20. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1.
Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y
Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
